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Abstract
Due to controversial evidence in the literature pertaining to the activity of plasminogen acti-
vator inhibitor-1 in platelets, we examined the effects of residual platelets present in plasma
(a potential pre-analytical variable) on various plasminogen activator inhibitor-1 and plas-
minogen activator inhibitor-1-related assays. Blood samples were collected from 151 indi-
viduals and centrifuged at 352 and 1500 g to obtain plasma with varying numbers of platelet.
In a follow-up study, blood samples were collected from an additional 23 individuals, from
whom platelet-poor (2000 g), platelet-containing (352 g) and platelet-rich plasma (200 g)
were prepared and analysed as fresh-frozen and after five defrost-refreeze cycles (to deter-
mine the contribution of in vitro platelet degradation). Plasminogen activator inhibitor-1 activ-
ity, plasminogen activator inhibitor-1 antigen, tissue plasminogen activator/plasminogen
activator inhibitor-1 complex, plasma clot lysis time, β-thromboglobulin and plasma platelet
count were analysed. Platelet α-granule release (plasma β-thromboglobulin) showed a sig-
nificant association with plasminogen activator inhibitor-1 antigen levels but weak associa-
tions with plasminogen activator inhibitor-1 activity and a functional marker of fibrinolysis,
clot lysis time. Upon dividing the study population into quartiles based on β-thromboglobulin
levels, plasminogen activator inhibitor-1 antigen increased significantly across the quartiles
while plasminogen activator inhibitor-1 activity and clot lysis time tended to increase in the 4th
quartile only. In the follow-up study, plasma plasminogen activator inhibitor-1 antigen was
also significantly influenced by platelet count in a concentration-dependent manner. Plasma
plasminogen activator inhibitor-1 antigen levels increased further after complete platelet deg-
radation. Residual platelets in plasma significantly influence plasma plasminogen activator
inhibitor-1 antigen levels mainly through release of latent plasminogen activator inhibitor-1
with limited effects on plasminogen activator inhibitor-1 activity, tissue plasminogen activator/
plasminogen activator inhibitor-1 complex or plasma clot lysis time. Platelets may however
also have functional effects on plasma fibrinolytic potential in the presence of high platelet
counts, such as in platelet-rich plasma.
PLOS ONE | DOI:10.1371/journal.pone.0171271 February 3, 2017 1 / 11
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Pieters M, Barnard SA, Loots DT, Rijken
DC (2017) The effects of residual platelets in
plasma on plasminogen activator inhibitor-1 and
plasminogen activator inhibitor-1-related assays.
PLoS ONE 12(2): e0171271. doi:10.1371/journal.
pone.0171271
Editor: Pablo Garcia de Frutos, Institut
d’Investigacions Biomediques de Barcelona, SPAIN
Received: October 12, 2016
Accepted: January 17, 2017
Published: February 3, 2017
Copyright: © 2017 Pieters et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported by grants from
the National Research Foundation (NRF) of South
Africa (Grant UID: 94213) (http://www.nrf.ac.za)
and the South African Medical Research Council
(http://www.mrc.ac.za). Opinions expressed and
conclusions arrived at, are those of the authors and
are not to be attributed to the NRF. The funders had
no role in study design, data collection and
Introduction
Plasminogen activator inhibitor type-1 (PAI-1) is a serine protease inhibitor (serpin) [1, 2],
which acts as a main inhibitor of fibrinolysis [3]. Elevated plasma PAI-1 levels have been asso-
ciated with a risk for developing atherothrombosis [4–6] due to its antifibrinolytic properties,
by reducing the clearance of fibrin in plaques [5], and also via its influence on cellular migra-
tion, matrix remodelling and activation of growth factors [7, 8]. Plasma PAI-1 exists either in
an active or latent form, or in complex with tissue plasminogen activator (tPA) [9–11]. The
active form of PAI-1 is unstable, with a half-life of approximately two to three hours, after
which it will spontaneously convert to the inactive, latent form [9, 12]. PAI-1 is produced by
various cells such as endothelial cells, hepatocytes, smooth muscle cells, adipocytes, and plate-
lets [11, 13]. In platelets, PAI-1 is stored in the alpha granules and is released during platelet
activation and aggregation [11, 14, 15].
Recently, there has been a debate about which form of PAI-1, or at least the relative propor-
tion of each form, is released from the platelet alpha granules. It was traditionally believed that
platelets store and release mainly latent PAI-1, since, only approximately 5–10% of PAI-1 anti-
gen (PAI-1ag) was shown to be active in lysed platelet-rich plasma [16]. More recent studies
however, suggest that platelets release a substantial amount of active PAI-1 [17–19]. This is
due to the observed de novo synthesis of PAI-1 within platelets, which was indicated to remain
active for over 24 hours [17]. Possible explanations for the contradictory evidence pertaining
to platelet PAI-1 activity, could be due to the different approaches used in these experiments
for preparing the platelet lysates (sonification and freezing and or thawing of the samples),
which have been reported to influence the detection of PAI-1 [18]. Furthermore, the conver-
sion of active PAI-1 to its latent state can be influenced by low temperatures, low pH and high
salt concentrations [20]. It is however not clear as to how the PAI-1, released from the alpha
granules of residual platelets in plasma, affects PAI-1 assays and PAI-1-related assays.
The overall aim of the study was therefore to investigate the effect of residual platelets in
plasma, on various PAI-1 and PAI-1-related assays: PAI-1 activity (PAI-1act), PAI-1 antigen
(PAI-1ag), and tPA/PAI-1 complex, as well as plasma fibrinolytic potential (a functional param-
eter of fibrinolysis, measured as plasma clot lysis time (CLT)). The study consisted of two sub-
studies. In the first, varying centrifugation speeds (352 and 1500 g) were used to prepare plate-
let-containing plasma, from 151 participants in the Sympathetic activity and Ambulatory Blood
Pressure in Africans (SABPA) study. The purpose of this sub-study was to determine the effect
of residual platelets in plasma on various PAI-1 assay results, by relating these assays to a marker
of platelet alpha granule release (beta thromboglobulin (βTG)). In this sub-study, absolute plate-
let counts were not measured, and additionally it was not possible to calculate to what degree
plasma PAI-1 levels were influenced by in vitro platelet activation and or degradation. Addition-
ally, Merolla et al. [21] found that different centrifugation speeds may result in different platelet
populations, which could also have had an effect on our results. The purpose of the second
study was, therefore, to determine the influence of actual platelet count on PAI-1ag, as the anti-
gen assay was the assay found to be significantly influenced by plasma platelet content in the
first sub-study. In the follow-up study, plasma was collected from 23 additional participants,
and platelet count and size, in addition to βTG and PAI-1ag concentrations, where determined
from three different plasma preparations: platelet-poor plasma (PPP– 2000 g), platelet-contain-
ing plasma (352 g, in keeping with the first sub-study protocol) and platelet-rich plasma (PRP–
200 g). PPP was collected in citrate tubes, containing platelet stabilisers, in order to provide
basal plasma PAI-1ag levels without any of the influencing effects of in vitro platelet activation
and/or degradation. Furthermore, the 352 g and 200 g citrated plasma samples were analysed
not only as fresh-frozen, but also after five defrost-refreeze cycles, ensuring complete alpha
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granule release from the platelets, in order to determine the total platelet PAI-1ag and βTG
content.
Materials and methods
Study population and ethics–SABPA study
The Sympathetic activity and Ambulatory Blood Pressure in Africans (SABPA) study, was a
cross-sectional study including 409 (202 men and 207 women) school teachers between the
ages of 25–60 years, from the North West Province, South Africa. Of these participants 151
individuals were randomly selected for inclusion in the present study. All samples were ana-
lysed at the same time. Exclusion criteria were: elevated ear temperature, dependence or abuse
of psychotropic substances, regular blood donors, and individuals vaccinated within the previ-
ous three months. The study complied with all applicable international regulations and the
Helsinki declaration for investigation of human participants. The study was approved by the
Health Research Ethics Committee (HREC) of the North-West University (NWU), Potchef-
stroom Campus (NWU-00016-10-A1).
Study population and ethics–follow-up study
Twenty three individuals from the same socio-demographic profile as the SABPA study partic-
ipants were recruited by means of a purposive sampling method from the Potchefstroom Cam-
pus of the NWU. The same inclusion and exclusion criteria as well as ethical principles were
adhered to. The study was approved by the HREC of the NWU, Potchefstroom Campus
(NWU-00016-10-A1). All samples were collected and analysed at the same time.
Blood collection–SABPA study
Fasting blood samples with minimum stasis were collected from the antebrachial vein before
10:00 am. 3.2% Citrate samples were used for the analysis of PAI-1 (activity, antigen and tPA/
PAI-1 complex), βTG and CLT. Samples were randomly divided into two groups. One half of
the study population samples were centrifuged at 352 g and the other half at 1500 g for 15 min-
utes at 20˚C to yield plasma containing a varying number of platelets. Aliquots were snap fro-
zen on dry ice and stored at -82˚C until analysis.
Blood collection–follow-up study
Fasting blood samples with minimum stasis were collected from the antebrachial vein before
10:00 am. Blood was collected into two 3.2% citrated tubes and one CTAD tube (a citrate tube
containing platelet stabilisers; theophylline, adenosine and dipyridamol). CTAD plasma was
prepared by centrifuging the samples at 2000 g for 30 minutes at 20˚C, to yield PPP with plate-
lets protected from in vitro activation or degradation. Two types of citrate plasma were pre-
pared by centrifuging one of the citrated tubes at 352 x g for 15 minutes at 20˚C, to yield
platelet-containing plasma, and the other tube at 200 x g for 10 minutes at 20˚C, to yield PRP.
These conditions were comparable to that of the SABPA study and also served the purpose to
provide information on standard plasma type preparations–PPP and PRP. All samples were
centrifuged within 20 min of collection.
Platelet count and size analyses were performed in fresh whole blood samples collected
both in citrate and CTAD tubes, as well as in the different plasma preparations described
above. The remaining plasma was then aliquoted, snap frozen on dry ice and stored at -82˚C.
The CTAD plasma samples and half of the aliquots of the two citrate plasma preparations, of
each individual, were thawed once only, by placing these in a 37˚C water bath for 10 minutes,
Residual platelets influence plasminogen activator inhibitor-1 assays
PLOS ONE | DOI:10.1371/journal.pone.0171271 February 3, 2017 3 / 11
immediately prior to PAI-1ag and βTG analyses. The second half of the citrated plasma sample
aliquots underwent five freeze-thaw cycles (x 5), once daily, prior to analysis, to ensure maxi-
mum platelet α-granule release. Fig 1 provides a schematic depiction of the study design.
Biochemical analysis
PAI-1act was measured using an indirect enzymatic method (Technozym PAI-1 Actibind,
Technoclone, Vienna, Austria), and PAI-1ag, using a two-site enzyme-linked immunosorbent
assay (ELISA) (TriniLIZE PAI-1ag, TCoag, Bray Ireland). tPA/PAI-1 complex was analysed
using a solid phase enzyme immunoassay, specific to PAI-1 complexed to tPA (Technoclone,
Vienna, Austria). An ELISA assay was used to measure βTG levels (Asserachrom1 βTG Diag-
nostica Stago, Asnières sur Seine, France). CLT was determined by studying the lysis of a tissue
factor-induced plasma clot by exogenous tPA. Changes in turbidity during clot formation and
lysis were monitored as described by Lisman et al. [22]. Tissue factor and tPA concentrations
were slightly modified to obtain comparable CLTs of approximately 60 minutes. The modified
concentrations were 17 mmol/L CaCl2, 60 ng/ml tPA (Actilyse, Boehringer Ingelheim, Ingel-
heim, Germany) and 10 μmol/L phospholipids vesicles (Rossix, Mo¨lndal, Sweden). Tissue fac-
tor was diluted 3000 times (Dade Innovin, Siemens Healthcare Diagnostics Inc., Marburg,
Germany). CLT was defined as the time from the midpoint, from clear to maximum turbidity
(representative of the clot formation), to the midpoint in the transition from maximum turbid-
ity to the final baseline turbidity (representative of the lysis of the clot) [22]. Platelet count and
mean platelet volume were determined with a Coulter AcT 5-part differential (5 diff) auto-
loader haematology analyser (Beckman Coulter, Fullerton, CA, USA).
Statistical analysis
The data was analysed with the computer software package Statistica (Statsoft Inc., Tulsa Okla-
homa, USA). A p-value of 0.05 or less was regarded as statistically significant. Descriptive data
is presented as median (25th; 75th percentiles) as most of the variables were not normally dis-
tributed. Kruskal-Wallis analysis of variance (ANOVA) with multiple comparisons of mean
post-hoc tests were used to compare differences in the PAI-1 and CLT assays, between popula-
tion sub-groups divided into quartiles of βTG levels. Correlations between variables were
determined both with Spearman Rank order and Pearson (for log transformed data) correla-
tion tests. Only the Spearman data is reported, as both correlation tests provided similar
Fig 1. Design of follow-up study.
doi:10.1371/journal.pone.0171271.g001
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results. Significant differences between correlation coefficients obtained were also calculated.
For the follow-up study, Wilcoxon-Matched pairs tests were used to determine significant dif-
ferences between plasma prepared at 200 and 352 g and also between fresh-frozen and 5 times
defrosted-refrozen samples.
Results
SABPA study
The study population included 151 participants, with a mean age of 45.7 (±8.75) years and a
BMI of 26.9 (±2.29). When comparing the samples prepared at the two different centrifugation
speeds, the 352 g group had significantly higher βTG (3263 vs 355 IU/mL; p< 0.0001) and
PAI-1ag (33.8 vs 20.8 ng/mL; p< 0.0001) levels, compared to the 1500 g group, with borderline
significantly higher PAI-1act (2.95 vs 1.91 U/mL; p = 0.03) and longer CLT (78.2 vs 74.4 min;
p = 0.04). No difference in tPA/PAI-1 complex (p = 0.09) was observed (Table 1).
When dividing the study population into quartiles according to plasma βTG levels
(Table 2), PAI-1ag increased consistently across the βTG quartiles. PAI-1act showed a signifi-
cant increase in the highest βTG quartile only, with CLT tending to be longer, without reach-
ing significance. No difference was observed in tPA/PAI-1 complex across the βTG quartiles.
βTG was furthermore correlated with PAI-1ag (r = 0.66; p<0.0001), demonstrating statistically
weaker correlations with PAI-1act (r = 0.22; p = 0.008); tPA/PAI-1 complex (r = 0.12; p = 0.13)
and CLT (r = 0.20; p = 0.02) (Table 3). CLT showed the strongest correlation with PAI-1act
(r = 0.74; p<0.0001).
Follow-up study
Table 4 presents the descriptive statistics of the follow-up study group. Platelet counts in the
citrated and CTAD whole blood were similar. The platelet count of the CTAD samples centri-
fuged at 2000 g was 1.00 (1.00–2.00) x 103/μL, confirming that it was indeed platelet poor (<10
x 103/μL). The platelet counts of the 352 g and 200 g plasma were 323 (257–440) x 103/μL and
523 (389–674) x 103/μL respectively. The 352 g plasma had a significantly lower mean platelet
volume (7.00 [6.65–7.60] fL) than the 200 g plasma (7.80 [7.00–8.30] fL), which in turn had a
similar mean platelet volume than that of the whole blood. βTG levels increased 60 fold and
150 fold in the 352 g and 200 g plasma respectively, compared to the PPP, while PAI-1ag levels
increased 15 and 22 fold respectively. In both the 352 g and 200 g plasma, the βTG levels of the
samples that underwent 5 freeze-thaw cycles, prior to analyses, were significantly lower than
that of the samples that were defrosted once only, prior to analysis, possibly due to instability
Table 1. Comparison of βTG, PAI-1 assays and CLT according to centrifugation speed in SABPA study.
Variable 352 g (n = 75) 1500 g (n = 75)
Median (25th; 75th percentiles) Median (25th; 75th percentiles) p-value(Mann-Whitney)
βTG (IU/mL) 3263 (2009; 4394) 355 (218; 584) <0.0001
PAI-1 ag (ng/mL) 33.8 (28.4; 42.4) 20.8 (16.7; 25.8) <0.0001
PAI-1act (U/mL) 2.95 (0.69; 8.72) 1.91 (0.25; 4.68) 0.03
tPA/PAI complex (ng/mL) 8.78 (6.59; 11.7) 7.90 (6.01; 10.2) 0.09
CLT (min) 78.2 (69.7; 86.4) 74.4 (69.7; 79.8) 0.04
βTG—beta thromboglobulin; CLT—clot lysis time; PAI-1 –plasminogen activator inhibitor-1 PAI-1act−PAI-1 activity; PAI-1 ag−PAI-1 antigen; tPA/PAI
complex—tissue plasminogen activator/PAI-1 complex.
doi:10.1371/journal.pone.0171271.t001
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of βTG (5% and 3% respectively), while PAI-1ag levels showed significant increases of 26% and
27% respectively.
When combining the different types of plasma, βTG had a highly significant correlation
with platelet count (r = 0.91, p<0.0001). When investigating the different types of plasma sepa-
rately, βTG levels correlated well with platelet count in the 352 g (r = 0.60, p = 0.002) and 200 g
(r = 0.70, p = 0.0002) plasma samples, with a smaller and non-significant correlation (r = 0.40,
p = 0.06) in the PPP (Table 5). For all the types of plasma combined, PAI-1ag and platelet count
were highly correlated (r = 0.91, p<0.0001). Compared with βTG, PAI-1ag showed even stronger
statistical correlations with platelet count in the 352 g (r = 0.85, p<0.0001) and 200 g (r = 0.81,
p<0.0001) plasma. None of the plasma preparations’ βTG levels correlated with whole blood
platelet count, while the correlation of PAI-1ag of the 200 g plasma with whole blood platelet
count, reached borderline significance (r = 0.4, p = 0.06). Furthermore, βTG and PAI-1ag corre-
lated significantly when combining the different types of plasma (r = 0.86, p<0.0001), however,
correlated negatively in PPP (r = -0.61, p = 0.002), with significant positive correlations in the
352 g (r = 0.55, p = 0.006) and 200 g (r = 0.74, p<0.0001) plasma separately (Table 6).
Discussion
This study investigated the effect of residual platelets present in plasma, on plasma PAI-1 and
PAI-1-related assay results. The presence of platelets in plasma significantly influenced plasma
PAI-1ag levels in a concentration dependent manner, likely due to an increase in mainly
plasma latent PAI-1. Only in the presence of large amounts of platelets such as in PRP,
Table 2. PAI-1act, PAI-1ag, tPA/PAI-1 complex and CLT according to βTG quartiles in SABPA study group.
Variable SAPBA study group
βTG 1st Quartile(341 IU/
mL)
βTG 2nd Quartile(341 IU/
mL—817 IU/mL)
βTG 3rd Quartile(817 IU/
mL—3263 IU/mL)
βTG 4th Quartile(>3263 IU/
mL)
ANOVA p-
value
n Median (25; 75%
percentile)
n Median (25; 75%
percentile)
n Median (25; 75%
percentile)
n Median (25; 75%
percentile)
PAI-1ag (ng/L) 37 20.4 (16.0; 25.8) * 38 21.5 (17.0; 26.7) * 37 29.6 (25.1; 39.7) # 37 40.7 (31.0; 42.9) # <0.0001
PAI-1act (U/mL) 34 2.56 (0.31; 4.89) 37 1.89 (0.20; 3.77) * 37 1.37 (0.41; 6.70) 36 5.65 (1.28; 10.3) # 0.03
tPA/PAI-1 complex
(ng/mL)
35 8.00 (6.36; 10.2) 37 7.55 (5.26; 10.1) 37 8.65 (6.28; 11.7) 38 9.06 (7.32; 11.3) 0.1
CLT (min) 34 75.4 (69.7; 79.5) 37 73.9 (69.7; 78.6) 36 76.6 (67.7; 84.1) 35 81.5 (71.6; 96.0) 0.06
ANOVA, analysis of co-variance; βTG, beta thromboglobulin; CLT, clot lysis time; PAI-1, plasminogen activator inhibitor-1; PAI-1act, PAI-1 activity; PAI-1 ag,
PAI-1 antigen; tPA/PAI-complex, tissue plasminogen activator/PAI-1 complex
* # Medians with different symbols differ significantly.
doi:10.1371/journal.pone.0171271.t002
Table 3. Spearman rank order correlations between βTG, PAI-1 assays and CLT in SABPA study group.
Variables βTG r (p-value) PAI-1 ag r (p-value) PAI-1actr (p-value) tPA/PAI-1complexr (p-value)
PAI-1 ag (ng/mL) 0.66 (<0.0001) - - -
PAI-1act (U/mL) 0.22 (0.008) * 0.43 (<0.0001) - -
tPA/PAI-1 complex (ng/mL) 0.12 (0.13) * 0.30 (0.0002) 0.64 (<0.0001) -
CLT (min) 0.20 (0.02) * 0.41 (<0.0001) 0.74 (<0.0001) 0.50 (<0.0001)
βTG, beta thromboglobulin; CLT, clot lysis time; PAI-1, plasminogen activator inhibitor-1; PAI-1act; PAI-1 activity; PAI-1 ag, PAI-1 antigen; tPA/PAI-complex,
tissue plasminogen activator/PAI-1 complex.
* Significantly weaker correlation with βTG than the correlation of PAI-1ag with βTG.
doi:10.1371/journal.pone.0171271.t003
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functional effects in terms of plasma fibrinolytic potential are seen, suggesting the presence of
a comparatively lower concentration of active PAI-1 in platelets. It was furthermore demon-
strated that platelets present in plasma, do not initially release all of their PAI-1 content and
that further release of PAI-1 can occur upon further / complete in vitro platelet degradation.
SABPA study
The SABPA study data indicated that βTG levels had a significantly stronger association with
PAI-1ag levels than any of the other PAI-1 variables or CLT. When dividing the study popula-
tion into βTG quartiles, PAI-1act and CLT increased in the highest βTG quartile only, suggest-
ing that there may be a small amount of active PAI-1 present in platelets. In agreement with
this, Serizawa et al. [23] found longer CLT in PRP than PPP which was ascribed to the pres-
ence of active PAI-1 in platelets. Since PAI-1ag is composed of latent PAI-1, active PAI-1 and
PAI-1 in complex with tPA, the data suggests that platelet alpha granule release largely contrib-
utes to increased plasma PAI-1ag, by increasing latent PAI-1. It was unfortunately not possible
Table 4. Descriptive statistics of the follow-up study group.
Variable Study population (n = 23)
Median (25th; 75th percentiles)
Gender: men / women (n) 12 / 11
Ethnicity: black / white (n) 11 / 12
Age (years) 36 (29; 42)
SBP (mm Hg) 120 (110; 130)
DBP (mm Hg) 80 (70; 80)
BMI (kg/m2) 26.4 (22.0; 28.4)
CTAD whole blood platelet count (x103/μL) 239 (195; 248)
Citrate whole blood platelet count (x103/μL) 234 (194; 257)
CTAD plasma 2000 g platelet count (x103/μL) 1.00 (1.00; 2.00)
Citrate plasma 352 g platelet count (x103/μL) 323 (257; 440)
Citrate plasma 200 g platelet count (x103/μL) 523 (389; 674)
Whole blood CTAD MPV (fL) 7.80 (7.40; 8.40)
Whole blood Citrate MPV (fL) 7.80 (7.20: 8.30)
MPV (fL) 352 g plasma 7.00 (6.65; 7.60)%
MPV (fL) 200 g plasma 7.80 (7.00; 8.30)%
βTG (IU/mL) CTAD 2000 g plasma 120 (92; 156)
βTG (IU/mL) 352 g x 1 plasma 7269 (6218; 8902)#
βTG (IU mL) 352 g x 5 plasma 6890 (5770; 7985)#
βTG (IU/mL) 200 g x 1 plasma 17683 (14703; 19089)^
βTG (IU/mL) 200 g x 5 plasma 17182 (14322; 18393)^
PAI-1ag (ng/mL) CTAD 2000 g plasma 5.16 (3.80; 11.5)
PAI-1ag (ng/mL) 352 g x 1 plasma 76.7 (64.1; 86.0)$
PAI-1ag (ng/mL) 352 g x 5 plasma 96.9 (74.7; 117)$
PAI-1ag (ng/mL) 200 g x 1 plasma 114.2 (90.6; 155)&
PAI-1ag (ng/mL) 200 g x 5 plasma 145 (115; 191)&
BMI, body mass index; βTG, beta thromboglobulin; CTAD, citrate-theophylline, adenosine, dipyridamol;
DBP, diastolic blood pressure; g, gravitational acceleration; PAI-1, plasminogen activator inhibitor-1; PAI-
1ag, PAI-1 antigen; SBP, systolic blood pressure; MPV, mean platelet volume
# ^ $ & % @ ** Median with the same symbol differ significantly between the 1x and 5 x frozen and defrosted
samples.
doi:10.1371/journal.pone.0171271.t004
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to measure plasma latent PAI-1 levels directly, as no such commercial assay is currently avail-
able. Latent PAI-1 is unable to inhibit tPA; therefore, the presence of latent PAI-1 in plasma
may lead to a falsely assumed increased fibrinolytic inhibitory capacity. The lack of increase in
CLT across the βTG quartiles, (apart from the highest quartile) confirms this. These results are
also in agreement with a study by Juhan-Vague et al. [24] who found PAI-1, released from
platelets, in vitro, to be mainly in the inactive form. Combined, this data suggests that platelets
likely contain both latent and active PAI-1, but that a high plasma platelet content (such as in
PRP) is required before the active PAI-1 present in platelets has functional effects on plasma
fibrinolytic potential.
Follow-up study
Data from the follow-up study, clearly demonstrated the significant effects of platelets present
in plasma, on plasma PAI-1ag levels. Platelet count and βTG and PAI-1ag levels were highly
correlated in the different plasma preparations containing platelets (352 g and 200 g), with no
significant associations in the PPP. PAI-1ag levels in PRP already tended to correlate with
whole blood platelet count. PAI-1ag levels, were furthermore, up to 22 fold higher in PRP
when compared to basal levels in PPP (which was exempted from the possible influence of
residual platelet content or in vitro platelet α-granule release), highlighting the magnitude of
the effect of platelets on plasma PAI-1ag levels, compared to other sources of PAI-1
Table 5. Spearman rank order correlations of βTG and PAI-1ag with whole blood, CTAD and citrate plasma platelet count of the follow-up study.
Variable Platelet count x103/μl (n = 23)
CTAD whole blood r
(p-value)
CTAD plasma (2000 g)
r (p-value)
Citrate whole blood r
(p-value)
Citrate plasma (352 g)r
(p-value)
Citrate plasma (200 g) r
(p-value)
βTG (IU/mL) CTAD 2000
g plasma
-0.14 (0.5) 0.40 (0.06) - - -
βTG (IU/mL) 352 g x 1
plasma
- - 0.12 (0.6) 0.6 (0.002) -
βTG (IU/mL) 200 g x 1
plasma
- - 0.20 (0.3) - 0.70 (0.0002)
PAI-1ag (ng/mL) CTAD
2000 g plasma
0.04 (0.9) -0.36 (0.09) - - -
PAI-1ag (ng/mL) 352 g x 1
plasma
- - 0.34 (0.1) 0.85 (<0.0001) -
PAI-1ag (ng/mL) 200 g x 1
plasma
- - 0.40 (0.06) - 0.81 (<0.0001)
βTG, beta thromboglobulin; CTAD, citrate-theophylline, adenosine, dipyridamol; g, gravitational acceleration; PAI-1, plasminogen activator inhibitor-1; PAI-
1 ag, PAI-1 antigen.
doi:10.1371/journal.pone.0171271.t005
Table 6. Spearman rank order correlations between βTG and PAI-1ag in the respective plasma prepa-
rations of the follow-up study.
Variables βTG—PAI-1agr (p-value)
CTAD plasma 2000 g -0.61 (0.002)
Citrate plasma 352 g x 1 0.55 (0.006)
Citrate plasma 200 g x 1 0.74 (<0.0001)
βTG, beta thromboglobulin; CTAD, citrate-theophylline, adenosine, dipyridamol; g, gravitational
acceleration; PAI-1, plasminogen activator inhibitor-1; PAI-1 ag, PAI-1 antigen.
doi:10.1371/journal.pone.0171271.t006
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(endothelial cells, hepatocytes, smooth muscle cells and adipocytes) [11, 13]. The additional
1.3 fold increase in plasma PAI-1ag, subsequent to maximal degradation (5 x freeze-that
cycles), suggests that in vitro platelet degradation can contribute to a further increase in plasma
PAI-1ag levels, confirming the necessity of the use of the correct plasma preparation protocols
to standardise platelet count and to ensure the preparation of platelet-poor plasma (<10 x 103/
μL). Differences in platelet size were also detected when comparing the 352 g and the 200 g
plasma, indicating the presence of different platelet populations in the samples centrifuged at
different speeds. Since platelets with larger sizes are known to be more metabolically active
than smaller platelets [25], platelet size, in addition to platelet count, most likely influence the
relationship between platelets present in plasma and PAI-1ag levels.
Although βTG is extensively used as a marker of platelet alpha granule release, it does have
limitations. The sensitivity of βTG as a marker of platelet activation and alpha granule release
can be influenced by various factors; including the choice of anticoagulant, and sample han-
dling and preparation procedures [26, 27]. The significant correlation between platelet count
and βTG (r = 0.91, p<0.0001) does however support its use as a proxy marker for the number
of platelets in plasma in our study populations. While PAI-1 activity may be influenced by
freeze-thaw cycles, we opted to work with frozen samples as this type of sample is most often
used in studies and therefore relevant to a larger audience. It should be noted that since all
samples were frozen at least once, possible effects of freezing on platelet function cannot be
excluded. All plasma preparations were however treated similarly making comparison between
the different preparations possible. Although samples were not specifically treated to prevent
possible in vitro conversion of active to latent PAI-1, samples were processed within 20 min-
utes after collection and snap frozen to limit in vitro conversion.
The results from the present study indicate that the content of the alpha granules released
from platelets in plasma, significantly influences plasma PAI-1ag levels, with limited effects on
PAI-1act, tPA/PAI-1 complex or fibrinolysis rate (measured as CLT). This effect on PAI-1ag is
thought to be largely due to an increased release of latent PAI-1 from platelets which is unable
to bind tPA and inhibit fibrinolysis. Due to the potential contribution of latent PAI-1 to PAI-
1ag levels, PAI-1act may be the more clinically useful assay to determine the fibrinolytic inhibi-
tor capacity of plasma. In plasma with a high platelet count, such as PRP, the component of
platelet PAI-1 that is active, may, however have functional effects by decreasing plasma fibri-
nolytic potential. These results suggest that PAI-1ag is more sensitive to the presence of plate-
lets in plasma, than other PAI-1 assays (PAI-1act and tPA/PAI-1 complex) or CLT but that
these assays may also be influenced by platelets when present in high numbers such as in PRP.
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